[go: up one dir, main page]

SI20851B - Mezoprogestini (modulatorji receptorja progesterona) kot komponenta pripravkov za nadomestno zdravljenje s hormoni (NZH) - Google Patents

Mezoprogestini (modulatorji receptorja progesterona) kot komponenta pripravkov za nadomestno zdravljenje s hormoni (NZH) Download PDF

Info

Publication number
SI20851B
SI20851B SI200020041A SI200020041A SI20851B SI 20851 B SI20851 B SI 20851B SI 200020041 A SI200020041 A SI 200020041A SI 200020041 A SI200020041 A SI 200020041A SI 20851 B SI20851 B SI 20851B
Authority
SI
Slovenia
Prior art keywords
mesoprogestins
hrt
replacement therapy
component
hormone replacement
Prior art date
Application number
SI200020041A
Other languages
English (en)
Other versions
SI20851A (sl
Inventor
Walter Elger
Kristof Chwalisz
Gerd Schubert
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of SI20851A publication Critical patent/SI20851A/sl
Publication of SI20851B publication Critical patent/SI20851B/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Ta izum se nanaša na uporabo mozoprogestinov kot farmacevtskih komponent za izdelavo zdravila za nadomestno zdravljenje s hormoni (NZH) in kot komponenta za kombinirano uporabo skupaj z estrogenom za izdelavo zdravila za NZH in v ustreznih metodah NZH in metodah za zdravljenje pomanjkanja hormonov in simptomov hormonske nepravilnosti. Mezoprogestini so definirani kot spojine, ki imajo tako agonistične kot antagonistične aktivnosti na receptorju progesterona (PR) in vivo. Stabilizirajo funkcijo PR na vmesni stopnji med agonistom in antagonistom. Ustreznih funkcijskih stanj ni mogoče doseči s progestini ali antiprogrestini. J867, J912, J956 in J1042 so prednostni mezoprogestini v smislu tega izuma.

Description

Mezoprogestini (modulatorji receptorja progesterona) kot komponenta pripravkov za nadomestno zdravljenje s hormoni (NZH)

Claims (6)

1. Uporaba mezoprogestinov, izbranih iz skupine, ki jo sestavljajo [4-[17P-metoksi-17a(metoksimetil)-3-oksoestra-4,9-dien-11p-il]benzaldehid-(1E)-oksimj (J867), [4-[17p(3-hidroksi17a-(metoksimetil)-3-oksoestra-4,9-dien-1ip-il]benzaldehid-(1E)-oksim] (J912) in [4-[17βmetoksi-17a-(metoksimetil)-3-oksoestra-4,9-dien-11 β-il] benzaldehid-( 1 E)-[O(etilamino)karbonil]oksim] (J956) kot farmacevtske sestavine za izdelavo zdravila za nadomestno zdravljenje s hormoni (NZH).
2. Uporaba mezoprogestina po zahtevku 1 skupaj z estrogenom za izdelavo zdravila za NZH.
3. Uporaba mezoprogestina po zahtevkih 1 ali 2 v dnevnem odmerku od 1,0 do 50,0 mg.
4. Uporaba po zahtevku 3, pri čemer je dnevni odmerek mezoprogestina 5,0 do 25,0 mg.
5. Uporaba po zahtevku 4, pri čemer je dnevni odmerek 10,0 do 25,0.
6. Uporaba po zahtevku 2, pri čemer je estrogen etinilestradiol, estradiol, estradiol ester ali 3sulfamat 17β-etinilestradiola ali 17p-estradiola.
SI200020041A 1999-08-31 2000-08-31 Mezoprogestini (modulatorji receptorja progesterona) kot komponenta pripravkov za nadomestno zdravljenje s hormoni (NZH) SI20851B (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38614099A 1999-08-31 1999-08-31
PCT/US2000/023771 WO2001034126A2 (en) 1999-08-31 2000-08-31 Mesoprogestins (progesterone receptor modulators) as a component of compositions for hormone replacement therapy (hrt)

Publications (2)

Publication Number Publication Date
SI20851A SI20851A (sl) 2002-10-31
SI20851B true SI20851B (sl) 2009-06-30

Family

ID=23524333

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200020041A SI20851B (sl) 1999-08-31 2000-08-31 Mezoprogestini (modulatorji receptorja progesterona) kot komponenta pripravkov za nadomestno zdravljenje s hormoni (NZH)

Country Status (33)

Country Link
EP (1) EP1605924B1 (sl)
JP (1) JP2003513908A (sl)
KR (1) KR100729311B1 (sl)
CN (1) CN1454088A (sl)
AR (1) AR025456A1 (sl)
AT (1) ATE413168T1 (sl)
AU (1) AU781836B2 (sl)
BG (1) BG65846B1 (sl)
BR (1) BR0013710A (sl)
CA (1) CA2383659C (sl)
CO (1) CO5200773A1 (sl)
CZ (1) CZ301412B6 (sl)
DE (1) DE60040764D1 (sl)
EA (1) EA007840B1 (sl)
EE (1) EE200200102A (sl)
ES (1) ES2316402T3 (sl)
HR (1) HRP20020266A2 (sl)
HU (1) HUP0202460A3 (sl)
IL (2) IL148417A0 (sl)
LT (1) LT5011B (sl)
LV (1) LV12942B (sl)
MX (1) MXPA02002190A (sl)
NO (1) NO20021000L (sl)
NZ (1) NZ517469A (sl)
PE (1) PE20010581A1 (sl)
PL (1) PL198798B1 (sl)
RO (1) RO122180B1 (sl)
RS (1) RS50396B (sl)
SI (1) SI20851B (sl)
SK (1) SK287121B6 (sl)
UA (1) UA75339C2 (sl)
WO (1) WO2001034126A2 (sl)
ZA (1) ZA200201621B (sl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10236405A1 (de) 2002-08-02 2004-02-19 Schering Ag Progesteronrezeptormodulatoren mit erhöhter antigonadotroper Aktivität für die weibliche Fertilitätskontrolle und Hormonersatztherapie
ATE338763T1 (de) * 2002-08-02 2006-09-15 Schering Ag Progesteronrezeptormodulatoren mit erhöhter antigonadotroper aktivität für die weibliche fertilitätskontrolle und hormonersatztherapie
US20040097591A1 (en) * 2002-11-18 2004-05-20 Kristof Chwalisz Use of selective progesterone receptor modulators for the treatment of androgen deficiency
RU2611370C1 (ru) * 2016-01-12 2017-02-21 Общество с ограниченной ответственностью Медицинская Корпорация "РАНА" Применение препарата Лаеннек для уменьшения или устранения проявления менопаузальных симптомов (варианты)

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2054271A (en) 1932-05-17 1936-09-15 Schering Kahlbaum Ag Production of crystallized hormone esters
DE699310C (de) 1936-11-20 1940-11-27 Chemische Ind Ges Verfahren zur Herstellung von in 3-Stellung veresterten Verbindungen vom Typus des Oestradiols
US2225419A (en) 1937-03-01 1940-12-17 Schering Corp Process for the conversion of 17-cisalcohols of the cyclopentanopolyhydrophenanthrene series into the corresponding 17-trans-alcohols
US2611773A (en) 1951-08-21 1952-09-23 Upjohn Co Estradiol 17-cyclopenetanepropionate
US2990414A (en) 1957-03-26 1961-06-27 Syntex Sa 17-undecenoate of estradiol
US4729999A (en) * 1984-10-12 1988-03-08 Bcm Technologies Antiestrogen therapy for symptoms of estrogen deficiency
MX9301121A (es) * 1992-03-02 1993-09-01 Schering Ag Metodo y equipo para la contracepcion oral y regulacion de la menstruacion con estrogeno/progestina/aniprogestina.
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
DE4225623C2 (de) * 1992-08-03 1994-06-30 Karl Hehl Verfahren zur Herstellung einer pulverförmigen Spritzgußmasse für die Herstellung von Porzellan und deren Verwendung
US5468736A (en) * 1993-02-25 1995-11-21 The Medical College Of Hampton Road Hormone replacement therapy
DE4332283A1 (de) * 1993-09-20 1995-04-13 Jenapharm Gmbh Neue 11-Benzaldoximestradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE4332284C2 (de) 1993-09-20 1997-05-28 Jenapharm Gmbh 11-Benzaldoxim-17beta-methoxy-17alpha-methoxymethyl-estradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
US5391557A (en) * 1993-10-15 1995-02-21 Eli Lilly And Company Methods for the treatment of peri-menopausal syndrome
EP0787002B1 (de) * 1994-10-24 2006-12-13 Schering Aktiengesellschaft Kompetitive progesteronantagonisten zur bedarfsorientierten weiblichen fertilitätskontrolle
DE19610635A1 (de) * 1996-03-11 1997-09-18 Schering Ag Sequentielle Estrogen/Progesteronantagonist-Kombination für die Hormonersatz-Therapie
CA2255863A1 (en) * 1996-06-25 1997-12-31 Akzo Nobel Nv Progestogen-anti-progestogen regimens
WO1998005679A2 (en) * 1996-08-05 1998-02-12 Duke University Mixed agonists of the progesterone receptor and assays therefor
DE19809845A1 (de) * 1998-03-03 1999-09-09 Jenapharm Gmbh S-substituierte 11beta-Benzaldoxim-estra-4,9-dien-kohlensäurethiolester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zubereitungen
TR200102041T2 (tr) * 1999-01-14 2001-12-21 Bayer Corporation Progesteron reseptör bağlama aktif maddeleri olarak ikameli 2-arilimino heterosaykıllar

Also Published As

Publication number Publication date
CA2383659C (en) 2009-02-10
CA2383659A1 (en) 2001-05-17
IL148417A0 (en) 2002-09-12
AU3633201A (en) 2001-06-06
LT5011B (lt) 2003-04-25
SK2972002A3 (en) 2002-07-02
RO122180B1 (ro) 2009-02-27
EP1605924B1 (en) 2008-11-05
NO20021000L (no) 2002-03-14
CN1454088A (zh) 2003-11-05
BG106443A (bg) 2002-09-30
CZ301412B6 (cs) 2010-02-24
RS50396B (sr) 2009-12-31
AR025456A1 (es) 2002-11-27
NO20021000D0 (no) 2002-02-28
JP2003513908A (ja) 2003-04-15
KR100729311B1 (ko) 2007-06-19
NZ517469A (en) 2004-01-30
AU781836B2 (en) 2005-06-16
CO5200773A1 (es) 2002-09-27
ATE413168T1 (de) 2008-11-15
PL198798B1 (pl) 2008-07-31
EP1605924A2 (en) 2005-12-21
HUP0202460A2 (hu) 2002-12-28
SI20851A (sl) 2002-10-31
ZA200201621B (en) 2004-08-25
KR20020027618A (ko) 2002-04-13
SK287121B6 (sk) 2009-12-07
UA75339C2 (en) 2006-04-17
EA007840B1 (ru) 2007-02-27
EE200200102A (et) 2003-04-15
HUP0202460A3 (en) 2004-04-28
MXPA02002190A (es) 2002-09-30
WO2001034126A3 (en) 2001-11-22
PL353931A1 (en) 2003-12-15
BG65846B1 (bg) 2010-03-31
WO2001034126A2 (en) 2001-05-17
EA200200285A1 (ru) 2002-08-29
LT2002037A (en) 2002-11-25
IL148417A (en) 2010-11-30
YU14102A (sh) 2006-01-16
WO2001034126A9 (en) 2002-09-12
CZ2002706A3 (cs) 2002-10-16
HRP20020266A2 (en) 2004-08-31
PE20010581A1 (es) 2001-06-04
ES2316402T3 (es) 2009-04-16
BR0013710A (pt) 2002-05-07
LV12942B (en) 2003-06-20
DE60040764D1 (de) 2008-12-18

Similar Documents

Publication Publication Date Title
BR9709934A (pt) Kit de terapia de reposição hormonal e/ou contraceptivo uso de unidades de dosagem diária consistindo essecialmente de um progestogênio e processo de preparação de um sistema de liberação de droga
MEP38008A (en) Drospirenone for hormone replacement therapy
HRP20070188B1 (hr) Farmaceutska kombinacija etinilestradiola i drospirenona za upotrebu kao kontracepcijskog sredstva
CA2281844A1 (en) Novel anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use
AR011480A1 (es) ACIL-ANILIDAS SUSTITUIDAS CON RADICALES (HETERO) CICLICOS, NO ESTEROIDALES, CON ACTIVIDAD GESTÁGENA Y ANDRoGENA MIXTA.
UA37259C2 (uk) Активна речовина для одержання лікарських засобів при лікуванні дисфункціональних маткових кровотеч
WO2006135638A3 (en) Tanaproget compositions containing ethinyl estradiol
TW200514560A (en) Pharmaceutical formulation for contraception and hormone-replacement therapy
CO5261567A1 (es) Uso de sulfamatos estrogenos biogenicos en una terapia de reemplazo de hormonas
BR0114665A (pt) Uso de antiprogestinas para a profilaxia e tratamento de doenças dependentes de hormÈnio
AR049112A1 (es) Composiciones, metodos y kit, para el tratamiento de trastorno disforico premenstrual
SI20851B (sl) Mezoprogestini (modulatorji receptorja progesterona) kot komponenta pripravkov za nadomestno zdravljenje s hormoni (NZH)
LT2002035A (lt) Mezoprogestinai (progesterono receptoriaus moduliatoriai) kaip moterų kontraceptikų komponentas
SI20852B (sl) Mezoprogestini (modulatorji receptorja progesterona) za zdravljenje in preprečevanje benignih hormonsko povzročenih ginekoloških motenj
EA200601089A1 (ru) Трансдермальная доставка гормонов без необходимости использования агентов, усиливающих проникновение
EA200501739A1 (ru) Композиция, содержащая антагонисты рецептора прогестерона и чистые антиэстрогены, предназначенные для профилактики и лечения гормонзависимых заболеваний
DK1652526T3 (da) Anvendelse af (11beta, 17beta)-11-(1,3-benzodioxol-5-yl)-17-hydroxy-17-(1-propynyl)-estra-4,9-dien-3-on i behandling af svær depressionslidelse
ATE419855T1 (de) Therapie für hormonersatz und depression enthaltend dienogest
WO1999045886A3 (en) New contraceptive kit for monotherapy
CA2248841A1 (en) Sequential oestrogen/progesterone antagonist combination for hormone replacement therapy
ATE395047T1 (de) Feste perorale arzneiform zur kontrazeption, die dienogest und ethinylestradiol enthält
MX2007009061A (es) Preparacion farmaceutica para la anticoncepcion oral.
BR0309621A (pt) Uso de estrógenos conjugados em combinação com trimegestona na terapia de substituição de hormÈnios
HRP20020666A8 (en) Drospirenone for hormone replacement therapy
JO2334B1 (en) Drospirenone for hormone replacement therapy

Legal Events

Date Code Title Description
SP73 Change of data on owner

Owner name: SCHERING AKTIENGESELLSCHAFT; DE

Effective date: 20041118

IF Valid on the event date
OU02 Decision according to article 73(2) ipa 1992, publication of decision on partial fulfilment of the invention and change of patent claims

Effective date: 20090422

SP73 Change of data on owner

Owner name: BAYER SCHERING PHARMA AG; DE

Effective date: 20090325

KO00 Lapse of patent

Effective date: 20110413